Skip to search
Skip to main content
Back to Search
Start Over
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
Authors :
MS Hematologie Infection & Immunity Regenerative Medicine and Stem Cells Cancer Vincent, Laure Gras, Luuk Ceballos, Patrice Finke, Jürgen Passweg, Jakob Harel, Stéphanie Rosinol, Laura Minnema, Monique Teipel, Raphael van Doesum, Jaap Hänel, Mathias Lenain, Pascal Botella-Garcia, Carmen Koenecke, Christian Ducastelle, Sophie Sanz, Jaime Schroyens, Wilfried Zuckerman, Tsila Monaco, Federico Koster, Linda de Wreede, Liesbeth Hayden, Patrick J Schönland, Stefan Yakoub-Agha, Ibrahim Beksac, Meral MS Hematologie Infection & Immunity Regenerative Medicine and Stem Cells Cancer Vincent, Laure Gras, Luuk Ceballos, Patrice Finke, Jürgen Passweg, Jakob Harel, Stéphanie Rosinol, Laura Minnema, Monique Teipel, Raphael van Doesum, Jaap Hänel, Mathias Lenain, Pascal Botella-Garcia, Carmen Koenecke, Christian Ducastelle, Sophie Sanz, Jaime Schroyens, Wilfried Zuckerman, Tsila Monaco, Federico Koster, Linda de Wreede, Liesbeth Hayden, Patrick J Schönland, Stefan Yakoub-Agha, Ibrahim Beksac, Meral
Publication Year :
2022
Details
Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1432118649
Document Type :
Electronic Resource